iShares Biotechnology ETF (IBB) Adds Gilead and Amgen on Oct. 8

gurufocus.com · 2026-10-12

In Thursday's session, one ETF was buying while none were selling, as iShares Biotechnology ETF (IBB) added to 231 positions and trimmed none. The fund deployed

TickrTrends take: Amgen's inclusion in the iShares Biotechnology ETF represents increased institutional positioning in the company, though this tracking addition does not alter fundamental valuation metrics. Given TickrTrends' current assessment that Amgen is overvalued within the Healthcare sector, investors focused on valuation should monitor whether ETF inflows create additional price pressure that widens the gap between market price and intrinsic value. The inclusion may boost trading volume and accessibility for passive investors, but valuation-conscious observers should remain attentive to whether the stock's premium to fair value persists or expands following this index event.

Read the full story at gurufocus.com →